SIB-1757
SIB-1757 is a pharmacological compound that acts as a selective antagonist for the mGluR5 receptor. It is primarily used in scientific research to investigate the role of mGluR5 receptors in various neurological and psychiatric disorders.
History[edit | edit source]
SIB-1757 was first synthesized and characterized in the late 1990s by a team of researchers at SIBIA Neurosciences, a biotechnology company based in La Jolla, California. The compound was developed as part of a larger effort to create selective antagonists for different types of metabotropic glutamate receptors (mGluRs), which are a family of G protein-coupled receptors involved in a variety of neurological processes.
Pharmacology[edit | edit source]
SIB-1757 is a non-competitive antagonist of the mGluR5 receptor, meaning it binds to a site on the receptor that is distinct from the glutamate binding site. This prevents the receptor from being activated by glutamate, but does not interfere with the binding of glutamate itself. The selectivity of SIB-1757 for mGluR5 receptors over other types of mGluRs is thought to be due to the unique structure of the compound, which allows it to fit into a specific pocket on the mGluR5 receptor.
Research Applications[edit | edit source]
SIB-1757 has been used in a variety of research studies to investigate the role of mGluR5 receptors in the brain. For example, it has been used to study the involvement of these receptors in neurodegenerative diseases such as Parkinson's disease and Huntington's disease, as well as psychiatric disorders like schizophrenia and depression. In addition, SIB-1757 has been used to explore the role of mGluR5 receptors in pain perception and drug addiction.
Safety and Toxicity[edit | edit source]
As a research compound, SIB-1757 is not intended for human consumption. However, studies in animals have suggested that it is relatively safe and well-tolerated at the doses typically used in research. The most common side effects observed in these studies include mild sedation and reduced motor activity, which are likely due to the role of mGluR5 receptors in regulating neural activity in the brain.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
